Literature DB >> 26390684

Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum.

J Prat, H Belhadj, J Berek, A Bermudez, N Bhatla, J Cain, L Denny, K Fujiwara, N Hacker, E Avall-Lundqvist, D Mutch, F Odicino, S Pecorelli, M Quinn, M A-F Seoud, S K Shrivastava.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26390684

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN： 0392-2936            Impact factor:   0.196


× No keyword cloud information.
  5 in total

Review 1.  Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.

Authors:  Maria Luisa Gasparri; Giovanni Grandi; Daniele Bolla; Beat Gloor; Sara Imboden; Pierluigi Benedetti Panici; Michael D Mueller; Andrea Papadia
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-11       Impact factor: 4.553

2.  Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study.

Authors:  Eduardo A Lacayo; Sara Velayati; Ahmed Elsakka; Lynn Brody; Joseph P Erinjeri; Etay Ziv; Franz E Boas; Constantinos T Sofocleous; Mikhail Silk; Vicky Makker; William P Tew; Hooman Yarmohammadi
Journal:  J Vasc Interv Radiol       Date:  2021-02-23       Impact factor: 3.682

3.  Transcriptomic analysis of stage 1 versus advanced adult granulosa cell tumors.

Authors:  Maria Alexiadis; Simon Chu; Dilys Leung; Jodee A Gould; Tom Jobling; Peter J Fuller
Journal:  Oncotarget       Date:  2016-03-22

4.  Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma.

Authors:  Wiebren A A Tjalma
Journal:  J Gynecol Oncol       Date:  2015-09-23       Impact factor: 4.401

5.  The application of 18F-FDG PET/CT in ovarian immature teratomas when pathological examination results contradict clinical observations: a case report.

Authors:  Manni Wang; Shaoxiong Jiang; Yiwen Zhang; Chong Jiang; Fan Xia; Weiliang Lyu; Xuelei Ma
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.